日期:
2020 年 — 2026 年
2020
2021
2022
2023
2024
2025
2026
影响因子:

XBB.1.5 spike protein COVID-19 vaccine induces broadly neutralizing and cellular immune responses against EG.5.1 and emerging XBB variants

XBB.1.5 刺突蛋白 COVID-19 疫苗可诱导针对 EG.5.1 和新出现的 XBB 变体的广泛中和和细胞免疫反应

Nita Patel, Jessica F Trost, Mimi Guebre-Xabier, Haixia Zhou, Jim Norton, Desheng Jiang, Zhaohui Cai, Mingzhu Zhu, Anthony M Marchese, Ann M Greene, Raburn M Mallory, Raj Kalkeri, Filip Dubovsky, Gale Smith

A prefusion-stabilized RSV F subunit vaccine elicits B cell responses with greater breadth and potency than a postfusion F vaccine

融合前稳定的 RSV F 亚单位疫苗比融合后 F 疫苗引发的 B 细胞反应更广泛、效力更强

Lauren A Chang, Emily Phung, Michelle C Crank, Kaitlyn M Morabito, Tonya Villafana, Filip Dubovsky, Judith Falloon, Mark T Esser, Bob C Lin, Grace L Chen, Barney S Graham, Tracy J Ruckwardt

SARS-CoV-2 variant B.1.1.7 is susceptible to neutralizing antibodies elicited by ancestral Spike vaccines

SARS-CoV-2 变体 B.1.1.7 易受祖先 Spike 疫苗引发的中和抗体的影响

Xiaoying Shen, Haili Tang, Charlene McDanal, Kshitij Wagh, Will Fischer, James Theiler, Hyejin Yoon, Dapeng Li, Barton F Haynes, Kevin O Sanders, Sandrasegaram Gnanakaran, Nick Hengartner, Rolando Pajon, Gale Smith, Filip Dubovsky, Gregory M Glenn, Bette Korber, David C Montefiori

Safety and immunogenicity of a live attenuated RSV vaccine in healthy RSV-seronegative children 5 to 24 months of age

减毒活 RSV 疫苗对 5 至 24 个月大的健康 RSV 血清阴性儿童的安全性和免疫原性

Elissa Malkin, Ram Yogev, Nazha Abughali, Joseph Sliman, C Kathy Wang, Fengrong Zuo, Chin-Fen Yang, Mark Eickhoff, Mark T Esser, Roderick S Tang, Filip Dubovsky